Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026. Neurology Program: ...

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...

H.C. Wainwright reaffirmed their Buy rating on Immunovant (NASDAQ:IMVT) shares with a price target of $51.00, aligning with the broader Wall Street sentiment. According to InvestingPro data, analyst ...

Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...

CSL’s balance sheet is in sound condition. Financial risk is low given low revenue cyclicality and product demand is being largely driven by chronic indications. We forecast CSL’s net debt to EBITDA ...

Roivant Sciences Ltd (ROIV) showcases strong financials and strategic advancements while navigating ongoing litigation and competitive pressures.

Takeda had hoped that Eohilia would be the first-ever treatment for EoE ... for chronic inflammatory demyelinating polyneuropathy (CIDP).

Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body’s immune system mistakenly attacks the ...

Multiple myeloma is part of the spectrum of diseases ranging from MGUS to plasma cell leukemia, and similar to MGUS, is characterized by proliferation of a plasma cell clone and subsequent ...

Most non-prescription medicines are not needed and can be stopped. Equipment: plastic medication syringe or dropper (not a spoon) Child's position: sitting up (never lying down) Place the syringe ...